Merus BV (NASDAQ:MRUS) — Market Cap & Net Worth
Market Cap & Net Worth: Merus BV (MRUS)
Merus BV (NASDAQ:MRUS) has a market capitalization of $6.83 Billion ($6.83 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2917 globally and #1018 in its home market, demonstrating a -7.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Merus BV's stock price $90.00 by its total outstanding shares 75847175 (75.85 Million). Analyse Merus BV cash flow conversion to see how efficiently the company converts income to cash.
Merus BV Market Cap History: 2016 to 2025
Merus BV's market capitalization history from 2016 to 2025. Data shows growth from $1.60 Billion to $6.83 Billion (25.61% CAGR).
Index Memberships
Merus BV is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.28% | #61 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.02% | #325 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.41% | #40 of 263 |
Weight: Merus BV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Merus BV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Merus BV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
91.44x
Merus BV's market cap is 91.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.60 Billion | $2.51 Million | -$47.44 Million | 637.90x | N/A |
| 2017 | $1.47 Billion | $21.91 Million | -$64.77 Million | 67.14x | N/A |
| 2018 | $1.06 Billion | $33.50 Million | -$24.71 Million | 31.70x | N/A |
| 2019 | $1.07 Billion | $27.76 Million | -$49.17 Million | 38.48x | N/A |
| 2020 | $1.33 Billion | $24.51 Million | -$70.00 Million | 54.24x | N/A |
| 2021 | $2.41 Billion | $43.15 Million | -$58.70 Million | 55.90x | N/A |
| 2022 | $1.17 Billion | $38.84 Million | -$122.52 Million | 30.21x | N/A |
| 2023 | $2.09 Billion | $39.81 Million | -$140.34 Million | 52.40x | N/A |
| 2024 | $3.19 Billion | $34.88 Million | -$207.85 Million | 91.44x | N/A |
Competitor Companies of MRUS by Market Capitalization
Companies near Merus BV in the global market cap rankings as of May 2, 2026.
Key companies related to Merus BV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Merus BV Historical Marketcap From 2016 to 2025
Between 2016 and today, Merus BV's market cap moved from $1.60 Billion to $ 6.83 Billion, with a yearly change of 25.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $6.83 Billion | +114.03% |
| 2024 | $3.19 Billion | +52.91% |
| 2023 | $2.09 Billion | +77.76% |
| 2022 | $1.17 Billion | -51.35% |
| 2021 | $2.41 Billion | +81.40% |
| 2020 | $1.33 Billion | +24.50% |
| 2019 | $1.07 Billion | +0.57% |
| 2018 | $1.06 Billion | -27.84% |
| 2017 | $1.47 Billion | -8.10% |
| 2016 | $1.60 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Merus BV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.83 Billion USD |
| MoneyControl | $6.83 Billion USD |
| MarketWatch | $6.83 Billion USD |
| marketcap.company | $6.83 Billion USD |
| Reuters | $6.83 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Merus BV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the… Read more